60 Degrees Pharmaceuticals, Inc.
SXTPNasdaqCIK 1946563HealthcareFiscal year ends Dec 31
Reports and events: 75 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2308:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-111864 |
| 2026-10-0607:45 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-106979 |
| 2026-09-1416:06 ET | 8-K | 8.01 Other events | 0001213900-26-099702 |
| 2026-09-0816:27 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-098056 |
| 2026-08-1415:34 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001554855-26-001860 |
| 2026-08-0616:07 ET | 8-K | 5.07 Shareholder vote results | 0001213900-26-086136 |
| 2026-08-0416:44 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-085235 |
| 2026-07-2016:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-079612 |
| 2026-07-0916:05 ET | 8-K | 8.01 Other events | 0001213900-26-076715 |
| 2026-07-0216:05 ET | DEF 14A | Proxy statementPeriod 2026-08-05 | 0001213900-26-074961 |
| 2026-06-0316:57 ET | 8-K | 8.01 Other events | 0001213900-26-064796 |
| 2026-05-1816:33 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001213900-26-058495 |
| 2026-05-1508:11 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001554855-26-001058 |
| 2026-03-3017:29 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001554855-26-000467 |
| 2026-03-2016:15 ET | 8-K | 8.01 Other events | 0001213900-26-032352 |
| 2026-03-1317:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-027756 |
| 2026-03-1216:36 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-027008 |
| 2026-02-1208:58 ET | 8-K | 8.01 Other events | 0001213900-26-015239 |
| 2026-01-2317:20 ET | 8-K | 3.01 Delisting notice; 7.01 Regulation FD disclosure | 0001213900-26-007330 |
| 2026-01-2116:05 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-006179 |
| 2026-01-0809:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-002359 |
| 2025-11-1313:31 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001554855-25-002032 |
| 2025-10-1016:15 ET | 8-K | 5.07 Shareholder vote results | 0001213900-25-098131 |
| 2025-09-0908:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-25-085853 |
| 2025-09-0516:20 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001213900-25-085040 |
| 2025-08-2719:17 ET | DEF 14A | Proxy statementPeriod 2025-10-08 | 0001213900-25-080878 |
| 2025-08-1314:45 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001554855-25-001009 |
| 2025-07-1816:57 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-065718 |
| 2025-07-0717:23 ET | S-1 | Registration statement | 0001213900-25-061842 |
| 2025-05-1510:07 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001213900-25-043779 |
| 2025-04-0908:31 ET | 8-K | 8.01 Other events | 0001213900-25-030102 |
| 2025-03-2716:06 ET | S-1/A | Registration statement, amended | 0001013762-25-003353 |
| 2025-03-2716:01 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001013762-25-003343 |
| 2025-02-1416:37 ET | S-1 | Registration statement | 0001213900-25-014334 |
| 2025-02-0616:41 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-010962 |
| 2025-01-3017:30 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-008463 |
| 2025-01-2816:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-007529 |
| 2025-01-0816:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-002070 |
| 2024-11-1413:44 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001213900-24-098195 |
| 2024-11-0617:26 ET | 8-K | 5.07 Shareholder vote results | 0001213900-24-095068 |
| 2024-10-1515:46 ET | DEF 14A | Proxy statementPeriod 2024-11-06 | 0001213900-24-087749 |
| 2024-10-0808:17 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-086079 |
| 2024-09-0616:10 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-076515 |
| 2024-08-2815:59 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-073351 |
| 2024-08-1415:55 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-068942 |
| 2024-08-1410:29 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001213900-24-068673 |
| 2024-08-1212:03 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-067535 |
| 2024-07-2616:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001013762-24-001604 |
| 2024-07-1617:28 ET | 8-K | 5.07 Shareholder vote results | 0001213900-24-061853 |
| 2024-07-0915:37 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-060093 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 27, 2026, 08:06 ET. Listed shows no prices and gives no investment advice.